[{"orgOrder":0,"company":"Adovate","sponsor":"Adial Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"ADO-5030","moa":"A2BR","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Adovate","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Adovate \/ Adovate","highestDevelopmentStatusID":"6","companyTruncated":"Adovate \/ Adovate"}]

Find Clinical Drug Pipeline Developments & Deals by Adovate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Hospitalar
                          Not Confirmed
                          Hospitalar
                          Not Confirmed

                          Details : Under the agreement, the ADO-5030 compound is being developed by Adovate as a potential first-line therapy for asthma.

                          Product Name : ADO-5030

                          Product Type : Other Small Molecule

                          Upfront Cash : $0.4 million

                          May 13, 2025

                          Lead Product(s) : ADO-5030

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Recipient : Adial Pharmaceuticals

                          Deal Size : $83.0 million

                          Deal Type : Agreement

                          blank